Related Experiment Videos
Protein kinase D in small cell lung cancer cells: rapid activation through protein kinase C
1Department of Medicine, School of Medicine and Molecular Biology Institute, University of California, Los Angeles 90095, USA.
Abstract:
Protein kinase C (PKC) is implicated in the regulation of a variety of important functions in small cell lung cancer (SCLC) cell lines, but the downstream signaling targets stimulated by PKCs in these cells remain poorly characterized. Here we report that treatment of the SCLC cell lines H 69, H 345, and H 510 with phorbol-12,13-dibutyrate (PDB) led to a rapid and striking activation of protein kinase D (PKD), a novel serine/threonine protein kinase distinct from all PKC isoforms. PKD activation induced by PDB in these SCLC cell lines was completely abrogated by treatment of the cells with the PKC inhibitor GF 109203X (GF I) at concentrations (0.5-2.5 microM) that did not inhibit PKD activity when added directly to the in vitro kinase assays. Treatment with the biologically active phorbol ester 12-O-tetradecanoylphorbol-13-acetate or with membrane-permeable diacylglycerols also stimulated PKD activation, which was also completely prevented by prior exposure of the cells to GF I. The PKC inhibitors Ro 31-8220 and Go 7874 also blocked PKD activation in response to PDB. Addition of the autocrine growth factor bombesin to cultures of H 345 cells induced significant PKD activation that also was prevented by GF I. Our results demonstrate, for the first time, the existence of a PKC/PKD pathway in SCLC cells and raise the possibility that PKD may be an important mediator of some of the biological responses elicited by PKC activation in SCLC cells.
Insights
Small cell lung cancer (SCLC) cells activate protein kinase D (PKD) through protein kinase C (PKC). This PKC/PKD pathway may mediate biological responses in SCLC, offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Protein kinase C (PKC) plays a role in small cell lung cancer (SCLC) cell functions.
- Downstream signaling targets of PKC in SCLC remain poorly understood.
Purpose of the Study:
- To investigate the downstream signaling targets of PKC in SCLC cell lines.
- To identify novel protein kinases activated by PKC in SCLC.
Main Methods:
- Treatment of SCLC cell lines (H 69, H 345, H 510) with phorbol esters (PDB, 12-O-tetradecanoylphorbol-13-acetate) and diacylglycerols.
- Inhibition studies using PKC inhibitors (GF 109203X, Ro 31-8220, Go 7874).
- Stimulation with autocrine growth factor bombesin.
Main Results:
- Phorbol ester treatment rapidly activated protein kinase D (PKD) in SCLC cell lines.
- PKD activation was abrogated by PKC inhibitors, confirming a PKC-dependent pathway.
- Bombesin stimulation also induced PKC-dependent PKD activation.
Conclusions:
- A novel PKC/PKD signaling pathway exists in SCLC cells.
- PKD may be a key mediator of PKC-induced biological responses in SCLC.
- This pathway presents a potential therapeutic target for SCLC treatment.